Reminder: ICCVAM webinar on Reverse Toxicokinetics – January 27, 2015

Home / Community Blog / Reminder: ICCVAM webinar on Reverse Toxicokinetics – January 27, 2015

Community Blog

Reminder: ICCVAM webinar on Reverse Toxicokinetics – January 27, 2015

Author: Marilyn Matevia, HSUS

Reminder from ICCVAM:

“ICCVAM TO PRESENT WEBINAR ON REVERSE TOXICOKINETIC MODELS ICCVAM is presenting a webinar on ‘Reverse Toxicokinetics: Using In Vitro Data to Estimate Exposures that Could Be Associated with Adverse Effects In Vivo’ on January 27. The webinar will focus on the development and application of reverse toxicokinetic models for extrapolation of high-throughput screening data to in vivo dosimetry. John Wambaugh, Ph.D., Physical Scientist at the EPA’s National Center for Computational Toxicology (NCCT), will provide an overview of the development of reverse toxicokinetic models. Barbara Wetmore, Ph.D., Senior Research Investigator at the Hamner Institutes for Health Sciences, will discuss the consideration of population variability and sensitive subpopulations in the use of these models. NICEATM and NCCT are hosting the webinar on behalf of ICCVAM.

Information about the webinar and a link to registration are available at http://ntp.niehs.nih.gov/go/ivive-webinar. Registration will be available until the webinar begins at 1:00 p.m. Eastern Standard Time.

The use of reverse toxicokinetic models to compare in vitro and in vivo estrogen receptor activity was the subject of a recent NICEATM publication in the journal Applied In Vitro Toxicology. The paper is available at http://online.liebertpub.com/doi/full/10.1089/aivt.2014.0005.

DRAFT EPA PROCESS DOCUMENT AVAILABLE FOR COMMENT A draft U.S. Environmental Protection Agency (EPA) document describing a ‘Process for Establishing and Implementing Alternative Approaches to Traditional In Vivo Acute Toxicity Studies’ is now available for comment. The document describes a transparent, stepwise process for evaluating and implementing alternative methods of testing for acute oral, dermal, and inhalation toxicity, along with skin and eye irritation and skin sensitization. In addition, there is a discussion of the three major phases of the process and the implications for reporting information under the Federal Insecticide, Fungicide, and Rodenticide Act.

The draft document is on the EPA website at http://www.epa.gov/pesticides/science/draft-alternative-test-method-guidance.pdf. Please submit comments on the document to Christopher Schlosser at schlosser.christopher@epa.gov. Comments will be accepted until March 10.”